110 related articles for article (PubMed ID: 20472345)
1. Secondary malignancies from prostate cancer radiation treatment: a risk analysis of the influence of target margins and fractionation patterns.
Daşu A; Toma-Daşu I; Franzén L; Widmark A; Nilsson P
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):738-46. PubMed ID: 20472345
[TBL] [Abstract][Full Text] [Related]
2. Modelling of organ-specific radiation-induced secondary cancer risks following particle therapy.
Stokkevåg CH; Fukahori M; Nomiya T; Matsufuji N; Engeseth GM; Hysing LB; Ytre-Hauge KS; Rørvik E; Szostak A; Muren LP
Radiother Oncol; 2016 Aug; 120(2):300-6. PubMed ID: 27424291
[TBL] [Abstract][Full Text] [Related]
3. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
[TBL] [Abstract][Full Text] [Related]
4. The comparison of radiotherapy techniques for treatment of the prostate cancer: the three-field vs. the four-field.
Milecki P; Piotrowski T; Dymnicka M
Neoplasma; 2004; 51(1):64-9. PubMed ID: 15004663
[TBL] [Abstract][Full Text] [Related]
5. Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer.
Murray L; Mason J; Henry AM; Hoskin P; Siebert FA; Venselaar J; Bownes P;
Radiother Oncol; 2016 Aug; 120(2):293-9. PubMed ID: 27370205
[TBL] [Abstract][Full Text] [Related]
6. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients.
Bhojani N; Capitanio U; Suardi N; Jeldres C; Isbarn H; Shariat SF; Graefen M; Arjane P; Duclos A; Lattouf JB; Saad F; Valiquette L; Montorsi F; Perrotte P; Karakiewicz PI
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):342-8. PubMed ID: 20117287
[TBL] [Abstract][Full Text] [Related]
7. Induced second cancers after prostate-cancer radiotherapy: no cause for concern?
Brenner DJ
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):637-9. PubMed ID: 16751057
[No Abstract] [Full Text] [Related]
8. Radical cystectomy in patients previously treated for localized prostate cancer.
Jayram G; Katz MH; Steinberg GD
Urology; 2010 Dec; 76(6):1430-3. PubMed ID: 20381130
[TBL] [Abstract][Full Text] [Related]
9. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up.
Liauw SL; Sylvester JE; Morris CG; Blasko JC; Grimm PD
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):669-73. PubMed ID: 16887293
[TBL] [Abstract][Full Text] [Related]
10. Second cancers in children treated with modern radiotherapy techniques.
Schneider U; Lomax A; Timmermann B
Radiother Oncol; 2008 Nov; 89(2):135-40. PubMed ID: 18707783
[TBL] [Abstract][Full Text] [Related]
11. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
[TBL] [Abstract][Full Text] [Related]
12. Practical aspects of inverse-planned intensity-modulated radiation therapy for prostate cancer: a radiation treatment planner's perspective.
Parker W; Patrocinio H
Can J Urol; 2005 Jun; 12 Suppl 2():48-52. PubMed ID: 16018834
[TBL] [Abstract][Full Text] [Related]
13. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
Vargas C; Yan D; Kestin LL; Krauss D; Lockman DM; Brabbins DS; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):141-9. PubMed ID: 16111582
[TBL] [Abstract][Full Text] [Related]
14. A prospective three-dimensional analysis about the impact of differences in the clinical target volume in prostate cancer irradiation on normal-tissue exposure. A potential for increasing the benefit/risk ratio.
Hille A; Töws N; Schmidberger H; Hess CF
Strahlenther Onkol; 2005 Dec; 181(12):789-95. PubMed ID: 16362789
[TBL] [Abstract][Full Text] [Related]
15. Prostatic irradiation is not associated with any measurable increase in the risk of subsequent rectal cancer.
Kendal WS; Eapen L; Macrae R; Malone S; Nicholas G
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):661-8. PubMed ID: 16545920
[TBL] [Abstract][Full Text] [Related]
16. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
Leborgne F; Fowler J
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
[TBL] [Abstract][Full Text] [Related]
17. Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
Luxton G; Hancock SL; Boyer AL
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):267-84. PubMed ID: 15093924
[TBL] [Abstract][Full Text] [Related]
18. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.
Di Muzio N; Fiorino C; Cozzarini C; Alongi F; Broggi S; Mangili P; Guazzoni G; Valdagni R; Calandrino R; Fazio F
Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):392-8. PubMed ID: 19056184
[TBL] [Abstract][Full Text] [Related]
19. Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.
Peeters ST; Hoogeman MS; Heemsbergen WD; Slot A; Tabak H; Koper PC; Lebesque JV
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1142-52. PubMed ID: 15939547
[TBL] [Abstract][Full Text] [Related]
20. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
